ACADIA PHARMACEUTICALS INC. Revenues
ACADIA PHARMACEUTICALS INC. (ACAD) reported Revenues of $231.04 million for the 3-month period ending 2023-12-31, per its 10-K filed 2024-02-28.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2024-02-28
- ACADIA PHARMACEUTICALS INC. revenues for the quarter ending 2023-12-31 was $231.04M, a 69.27% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. revenues for the quarter ending 2023-09-30 was $211.70M, a 61.96% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. revenues for the quarter ending 2023-06-30 was $165.24M, a 22.79% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. revenues for the quarter ending 2023-03-31 was $118.46M, a 2.59% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. revenues for fiscal 2023 was $726.44M, a 40.45% increase from fiscal 2022.
- ACADIA PHARMACEUTICALS INC. revenues for fiscal 2022 was $517.24M, a 6.83% increase from fiscal 2021.
- ACADIA PHARMACEUTICALS INC. revenues for fiscal 2021 was $484.14M, a 9.60% increase from fiscal 2020.
- ACADIA PHARMACEUTICALS INC. revenues for fiscal 2020 was $441.75M, a 30.28% increase from fiscal 2019.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2023-12-31 | $231.04M 10-K · filed 2024-02-28 | $442.74M derived: sum of 2 quarters · filed 2024-02-28 | $607.98M derived: sum of 3 quarters · filed 2024-02-28 | $726.44M 10-K · filed 2024-02-28 |
| 2023-09-30 | $211.70M 10-K · filed 2024-02-28 | $376.93M derived: sum of 2 quarters · filed 2024-02-28 | $495.40M derived: sum of 3 quarters · filed 2024-02-28 | $631.89M derived: sum of 4 quarters · filed 2024-02-28 |
| 2023-06-30 | $165.24M 10-K · filed 2024-02-28 | $283.70M derived: sum of 2 quarters · filed 2024-02-28 | $420.19M derived: sum of 3 quarters · filed 2024-02-28 | $550.90M derived: sum of 4 quarters · filed 2024-02-28 |
| 2023-03-31 | $118.46M 10-K · filed 2024-02-28 | $254.95M derived: sum of 2 quarters · filed 2024-02-28 | $385.67M derived: sum of 3 quarters · filed 2024-02-28 | $520.23M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-12-31 | $136.49M 10-K · filed 2024-02-28 | $267.20M derived: sum of 2 quarters · filed 2024-02-28 | $401.77M derived: sum of 3 quarters · filed 2024-02-28 | $517.24M 10-K · filed 2024-02-28 |
| 2022-09-30 | $130.71M 10-K · filed 2024-02-28 | $265.28M derived: sum of 2 quarters · filed 2024-02-28 | $380.75M derived: sum of 3 quarters · filed 2024-02-28 | $511.50M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $134.56M 10-K · filed 2024-02-28 | $250.03M derived: sum of 2 quarters · filed 2024-02-28 | $380.79M derived: sum of 3 quarters · filed 2024-02-28 | $512.40M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $115.47M 10-K · filed 2024-02-28 | $246.23M derived: sum of 2 quarters · filed 2024-02-28 | $377.84M derived: sum of 3 quarters · filed 2024-02-28 | $493.06M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $130.76M 10-K · filed 2023-02-28 | $262.37M derived: sum of 2 quarters · filed 2023-02-28 | $377.59M derived: sum of 3 quarters · filed 2023-02-28 | $484.14M 10-K · filed 2023-02-28 |
| 2021-09-30 | $131.61M 10-K · filed 2023-02-28 | $246.83M derived: sum of 2 quarters · filed 2023-02-28 | $353.39M derived: sum of 3 quarters · filed 2023-02-28 | $474.39M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $115.22M 10-K · filed 2023-02-28 | $221.78M derived: sum of 2 quarters · filed 2023-02-28 | $342.78M derived: sum of 3 quarters · filed 2023-02-28 | $463.36M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $106.55M 10-K · filed 2023-02-28 | $227.56M derived: sum of 2 quarters · filed 2023-02-28 | $348.14M derived: sum of 3 quarters · filed 2023-02-28 | $458.24M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $441.75M 10-K · filed 2022-03-01 | |||
| 2020-12-30 | $121.01M 10-K · filed 2022-03-01 | $241.58M derived: sum of 2 quarters · filed 2022-03-01 | $351.69M derived: sum of 3 quarters · filed 2022-03-01 | $441.75M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-09-30 | $120.58M 10-K · filed 2022-03-01 | $230.68M derived: sum of 2 quarters · filed 2022-03-01 | $320.75M derived: sum of 3 quarters · filed 2022-03-01 | $419.07M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $110.10M 10-K · filed 2022-03-01 | $200.17M derived: sum of 2 quarters · filed 2022-03-01 | $298.50M derived: sum of 3 quarters · filed 2022-03-01 | $393.08M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $90.07M 10-K · filed 2022-03-01 | $188.39M derived: sum of 2 quarters · filed 2022-03-01 | $282.98M derived: sum of 3 quarters · filed 2022-03-01 | $366.19M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $98.33M 10-K · filed 2021-02-25 | $192.91M derived: sum of 2 quarters · filed 2021-02-25 | $276.12M derived: sum of 3 quarters · filed 2021-02-25 | $339.08M 10-K · filed 2021-02-25 |
| 2019-09-30 | $94.59M 10-K · filed 2021-02-25 | $177.79M derived: sum of 2 quarters · filed 2021-02-25 | $240.75M derived: sum of 3 quarters · filed 2021-02-25 | $300.32M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $83.20M 10-K · filed 2021-02-25 | $146.16M derived: sum of 2 quarters · filed 2021-02-25 | $205.74M derived: sum of 3 quarters · filed 2021-02-25 | $264.04M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $62.96M 10-K · filed 2021-02-25 | $122.53M derived: sum of 2 quarters · filed 2021-02-25 | $180.84M derived: sum of 3 quarters · filed 2021-02-25 | $237.90M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $59.57M 10-K · filed 2020-02-27 | $117.88M derived: sum of 2 quarters · filed 2020-02-27 | $174.94M derived: sum of 3 quarters · filed 2020-02-27 | $223.81M 10-K · filed 2020-02-27 |
| 2018-09-30 | $58.30M 10-K · filed 2020-02-27 | $115.37M derived: sum of 2 quarters · filed 2020-02-27 | $164.24M derived: sum of 3 quarters · filed 2020-02-27 | $207.80M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $57.06M 10-K · filed 2020-02-27 | $105.93M derived: sum of 2 quarters · filed 2020-02-27 | $149.49M derived: sum of 3 quarters · filed 2020-02-27 | $185.07M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $48.87M 10-K · filed 2020-02-27 | $92.43M derived: sum of 2 quarters · filed 2020-02-27 | $128.01M derived: sum of 3 quarters · filed 2020-02-27 | $158.48M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $43.56M 10-K · filed 2019-02-27 | $79.14M derived: sum of 2 quarters · filed 2019-02-27 | $109.61M derived: sum of 3 quarters · filed 2019-02-27 | $124.90M 10-K · filed 2019-02-27 |
| 2017-09-30 | $35.58M 10-K · filed 2019-02-27 | $66.05M derived: sum of 2 quarters · filed 2019-02-27 | $81.34M 10-Q · filed 2017-11-07 | $93.30M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | $30.48M 10-K · filed 2019-02-27 | $45.76M 10-Q · filed 2017-08-08 | $57.72M derived: sum of 3 quarters · filed 2019-02-27 | $62.99M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-03-31 | $15.29M 10-K · filed 2019-02-27 | $27.25M derived: sum of 2 quarters · filed 2019-02-27 | $32.52M derived: sum of 3 quarters · filed 2019-02-27 | $32.61M derived: sum of 4 quarters · filed 2019-02-27 |
| 2016-12-31 | $11.96M 10-K · filed 2018-02-27 | $17.23M derived: sum of 2 quarters · filed 2018-02-27 | $17.33M derived: sum of 3 quarters · filed 2018-02-27 | $17.33M 10-K · filed 2018-02-27 |
| 2016-09-30 | $5.27M 10-K · filed 2018-02-27 | $5.37M derived: sum of 2 quarters · filed 2018-02-27 | $5.37M 10-Q · filed 2017-11-07 | $5.39M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | $97.00K 10-K · filed 2018-02-27 | $101.00K 10-Q · filed 2017-08-08 | $118.00K derived: sum of 3 quarters · filed 2018-02-27 | $157.00K derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | $4.00K 10-K · filed 2018-02-27 | $21.00K derived: sum of 2 quarters · filed 2018-02-27 | $60.00K derived: sum of 3 quarters · filed 2018-02-27 | $61.00K derived: sum of 4 quarters · filed 2018-02-27 |
| 2015-12-31 | $17.00K 10-K · filed 2017-02-28 | $56.00K derived: sum of 2 quarters · filed 2017-02-28 | $57.00K derived: sum of 3 quarters · filed 2017-02-28 | $61.00K 10-K · filed 2018-02-27 |
| 2015-09-30 | $39.00K 10-K · filed 2017-02-28 | $40.00K derived: sum of 2 quarters · filed 2017-02-28 | $44.00K 10-Q · filed 2016-11-07 | $91.00K derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-06-30 | $1.00K 10-K · filed 2017-02-28 | $5.00K 10-Q · filed 2016-08-04 | $52.00K derived: sum of 3 quarters · filed 2017-02-28 | $67.00K derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-03-31 | $4.00K 10-K · filed 2017-02-28 | $51.00K derived: sum of 2 quarters · filed 2017-02-28 | $66.00K derived: sum of 3 quarters · filed 2017-02-28 | $94.00K derived: sum of 4 quarters · filed 2017-02-28 |
| 2014-12-31 | $47.00K 10-K · filed 2016-02-29 | $62.00K derived: sum of 2 quarters · filed 2016-02-29 | $90.00K derived: sum of 3 quarters · filed 2016-02-29 | $120.00K 10-K · filed 2017-02-28 |
| 2014-09-30 | $15.00K 10-K · filed 2016-02-29 | $43.00K derived: sum of 2 quarters · filed 2016-02-29 | $72.00K 10-Q · filed 2015-11-05 | $110.00K derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $28.00K 10-K · filed 2016-02-29 | $58.00K 10-Q · filed 2015-08-06 | $95.00K derived: sum of 3 quarters · filed 2016-02-29 | $335.00K derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $30.00K 10-K · filed 2016-02-29 | $67.00K derived: sum of 2 quarters · filed 2016-02-29 | $307.00K derived: sum of 3 quarters · filed 2016-02-29 | $758.00K derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | $37.00K 10-K · filed 2015-02-26 | $277.00K derived: sum of 2 quarters · filed 2015-02-26 | $728.00K derived: sum of 3 quarters · filed 2015-02-26 | $1.15M 10-K · filed 2016-02-29 |
| 2013-09-30 | $240.00K 10-K · filed 2015-02-26 | $691.00K derived: sum of 2 quarters · filed 2015-02-26 | $1.11M 10-Q · filed 2014-11-10 | $1.49M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-06-30 | $451.00K 10-K · filed 2015-02-26 | $868.00K 10-Q · filed 2014-08-05 | $1.25M derived: sum of 3 quarters · filed 2015-02-26 | $4.73M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-03-31 | $417.00K 10-K · filed 2015-02-26 | $797.00K derived: sum of 2 quarters · filed 2015-02-26 | $4.28M derived: sum of 3 quarters · filed 2015-02-26 | $4.87M derived: sum of 4 quarters · filed 2015-02-26 |
| 2012-12-31 | $380.00K 10-K · filed 2014-02-27 | $3.86M derived: sum of 2 quarters · filed 2014-02-27 | $4.46M derived: sum of 3 quarters · filed 2014-02-27 | $4.91M 10-K · filed 2015-02-26 |
| 2012-09-30 | $3.48M 10-K · filed 2014-02-27 | $4.08M derived: sum of 2 quarters · filed 2014-02-27 | $4.53M 10-Q · filed 2013-11-06 | $5.12M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | $599.00K 10-K · filed 2014-02-27 | $1.05M 10-Q · filed 2013-08-06 | $1.64M derived: sum of 3 quarters · filed 2014-02-27 | $2.22M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | $450.00K 10-K · filed 2014-02-27 | $1.04M derived: sum of 2 quarters · filed 2014-02-27 | $1.62M derived: sum of 3 quarters · filed 2014-02-27 | $2.08M derived: sum of 4 quarters · filed 2014-02-27 |
| 2011-12-31 | $588.00K 10-K · filed 2013-03-12 | $1.17M derived: sum of 2 quarters · filed 2013-03-12 | $1.63M derived: sum of 3 quarters · filed 2013-03-12 | $2.07M 10-K · filed 2014-02-27 |
| 2011-09-30 | $584.00K 10-K · filed 2013-03-12 | $1.04M derived: sum of 2 quarters · filed 2013-03-12 | $1.48M 10-Q · filed 2012-11-05 | $36.88M derived: sum of 4 quarters · filed 2013-03-12 |
| 2011-06-30 | $460.00K 10-K · filed 2013-03-12 | $895.00K 10-Q · filed 2012-08-08 | $36.30M derived: sum of 3 quarters · filed 2013-03-12 | $38.60M derived: sum of 4 quarters · filed 2013-03-12 |
| 2011-03-31 | $435.00K 10-K · filed 2013-03-12 | $35.84M derived: sum of 2 quarters · filed 2013-03-12 | $38.14M derived: sum of 3 quarters · filed 2013-03-12 | $40.44M derived: sum of 4 quarters · filed 2013-03-12 |
| 2010-12-31 | $35.40M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-12 | $37.70M derived: sum of 2 quarters · filed 2013-03-12 | $40.00M derived: sum of 3 quarters · filed 2013-03-12 | $42.13M 10-K · filed 2013-03-12 |
| 2010-09-30 | $2.30M 10-Q · filed 2011-11-09 | $4.60M derived: sum of 2 quarters · filed 2011-11-09 | $6.73M 10-Q · filed 2011-11-09 | |
| 2010-06-30 | $2.30M 10-Q · filed 2011-08-10 | $4.43M 10-Q · filed 2011-08-10 | ||
| 2009-12-31 | $6.40M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |